<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36928619</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice.</ArticleTitle><Pagination><StartPage>515</StartPage><EndPage>521</EndPage><MedlinePgn>515-521</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27818</ELocationID><Abstract><AbstractText Label="INTRODUCTION/AIMS">In amyotrophic lateral sclerosis (ALS) caused by superoxide dismutase 1 (SOD1) gene mutations (SOD1-ALS), the antisense oligonucleotide tofersen had been investigated in a phase III study (VALOR) and subsequently introduced in an expanded access program. In this study we assess neurofilament light chain (NfL) before and during tofersen treatment.</AbstractText><AbstractText Label="METHODS">In six SOD1-ALS patients treated with tofersen at three specialized ALS centers in Germany, NfL in cerebrospinal fluid (CSF-NfL) and/or serum (sNfL) were investigated using the ALS Functional Rating Scale Revised (ALSFRS-R) and ALS progression rate (ALS-PR), defined by monthly decline of ALSFRS-R.</AbstractText><AbstractText Label="RESULTS">Three of the six SOD1-ALS patients reported a negative family history. Three patients harbored a homozygous c.272A &gt; C, p.(Asp91Ala) mutation. These and two other patients showed slower progressing ALS (defined by ALS-PR &lt;0.9), whereas one patient demonstrated rapidly progressing ALS (ALS-PR&#x2009;=&#x2009;2.66). Mean treatment duration was 6.5 (range 5 to 8) months. In all patients, NfL decreased (mean CSF-NfL: -66%, range -52% to -86%; mean sNfL: -62%, range -36% to -84%). sNfL after 5&#x2009;months of tofersen treatment was significantly reduced compared with the nearest pretreatment measurement (P&#x2009;=&#x2009;.017). ALS-PR decreased in two patients, whereas no changes in ALSFRS-R were observed in four participants who had very low ALS-PR or ALSFRS-R values before treatment.</AbstractText><AbstractText Label="DISCUSSION">In this case series, the significant NfL decline after tofersen treatment confirmed its value as response biomarker in an expanded clinical spectrum of SOD1-ALS. Given the previously reported strong correlation between sNfL and ALS progression, the NfL treatment response supports the notion of tofersen having disease-modifying activity.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Muscle &amp; Nerve published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-2736-7350</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ambulanzpartner Soziotechnologie APST GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schumann</LastName><ForeName>Peggy</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Ambulanzpartner Soziotechnologie APST GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weydt</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department for Neurodegenerative Disorders and Gerontopsychiatry, Bonn University, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Research Site Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petri</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koc</LastName><ForeName>Yasemin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spittel</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ambulanzpartner Soziotechnologie APST GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernsen</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department for Neurodegenerative Disorders and Gerontopsychiatry, Bonn University, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;nther</LastName><ForeName>Ren&#xe9;</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t Dresden, University Hospital Carl Gustav Carus, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Research Site Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weishaupt</LastName><ForeName>Jochen H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Neurology Department, Division for Neurodegenerative Diseases, University Medicine Mannheim, Heidelberg University, Mannheim Center for Translational Medicine, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dreger</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolzarek</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Ambulanzpartner Soziotechnologie APST GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kettemann</LastName><ForeName>Dagmar</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norden</LastName><ForeName>Jenny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boentert</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6133-1397</Identifier><AffiliationInfo><Affiliation>Department of Neurology, M&#xfc;nster University Hospital, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidovic</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t Dresden, University Hospital Carl Gustav Carus, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meisel</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Immunology, Labor Berlin-Charit&#xe9; Vivantes GmbH, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, BIH Center for Regenerative Therapies, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;nch</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ambulanzpartner Soziotechnologie APST GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2473-4116</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;rtv&#xe9;lyessy</LastName><ForeName>P&#xe9;ter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Research Site Magdeburg, Magdeburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2NU6F9601K</RegistryNumber><NameOfSubstance UI="C000709090">tofersen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">neurofilament light chain</Keyword><Keyword MajorTopicYN="N">tofersen</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>17</Day><Hour>9</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36928619</ArticleId><ArticleId IdType="doi">10.1002/mus.27818</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Rosen D, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59-62.</Citation></Reference><Reference><Citation>M&#xfc;ller K, Brenner D, Weydt P, et al. Comprehensive analysis of the mutation spectrum in 301 German ALS families. J Neurol Neurosurg Psychiatry. 2018;89:817-827.</Citation></Reference><Reference><Citation>Bunton-Stasyshyn RK, Saccon RA, Fratta P, Fisher EM. SOD1 function and its implications for amyotrophic lateral sclerosis pathology: new and renascent themes. Neuroscientist. 2015;21:519-529.</Citation></Reference><Reference><Citation>McCampbell A, Cole T, Wegener AJ, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Invest. 2018;128:3558-3567.</Citation></Reference><Reference><Citation>Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022;387:1099-1110.</Citation></Reference><Reference><Citation>Miller TM, Cudkowicz ME, Shaw PJ, et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383:109-119.</Citation></Reference><Reference><Citation>Hardiman O, van den Berg LH. The beginning of genomic therapies for ALS. N Engl J Med. 2020;383:180-181.</Citation></Reference><Reference><Citation>Feneberg E, Oeckl P, Steinacker P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. 2018;90:e22-e30.</Citation></Reference><Reference><Citation>Steinacker P, Feneberg E, Weishaupt J, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2016;87:12-20.</Citation></Reference><Reference><Citation>Thouvenot E, Demattei C, Lehmann S, et al. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur J Neurol. 2020;27:251-257.</Citation></Reference><Reference><Citation>Benatar M, Zhang L, Wang L, et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95:e59-e69.</Citation></Reference><Reference><Citation>Dreger M, Steinbach R, Gaur N, et al. Cerebrospinal fluid neurofilament light chain (NfL) predicts disease aggressiveness in amyotrophic lateral sclerosis: an application of the D50 disease progression model. Front Neurosci. 2021;15:651651.</Citation></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453-1457.</Citation></Reference><Reference><Citation>Meyer T, Spittel S, Grehl T, et al. Remote digital assessment of amyotrophic lateral sclerosis functional rating scale---a multicenter observational study. Amyotroph Lateral Scler Frontotemporal Degener. 2022;1:1-10. doi:10.1080/21678421.2022.2104649</Citation></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (phase III). J Neurol Sci. 1999;169:13-21.</Citation></Reference><Reference><Citation>Maier A, Boentert M, Reilich P, et al. ALSFRS-R-SE: an adapted, annotated, and self-explanatory version of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale. Neurol Res Pract. 2022;4:60.</Citation></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66:265-267.</Citation></Reference><Reference><Citation>Wicks P, Massagli MP, Wolf C, Heywood J. Measuring function in advanced ALS: validation of ALSFRS-EX extension items. Eur J Neurol. 2009;16:353-359.</Citation></Reference><Reference><Citation>Meyer T, Maier A, Uzelac Z, et al. Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen. Eur J Neurol. 2021;28:2582-2595.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>